Johnson & Johnson (BSP:JNJB34)
R$ 60.12 0 (0%) Market Cap: 2.18 Til Enterprise Value: 2.27 Til PE Ratio: 24.52 PB Ratio: 5.08 GF Score: 76/100

Johnson & Johnson at UBS Global Healthcare Conference Transcript

May 24, 2022 / 02:00PM GMT
Release Date Price: R$57.81 (+0.93%)
Laura Sutcliffe
UBS Investment Bank, Research Division - Equity Research Analyst

Good morning, everyone, and welcome back to day 2 of the UBS Global Healthcare Conference. I'm delighted to be joined on stage by Dr. Mathai Mammen, who is Head of Pharmaceuticals R&D at Johnson & Johnson.

My name is Laura Sutcliffe. I'm a pharmaceuticals analyst here at UBS. And I'm very happy to be spending the next 36 minutes and 24 seconds talking to you about R&D activity at J&J.

If you'd like to ask a question, we're going to throw you a curve ball, which is that the QR codes currently don't do anything when it comes to talking to the iPad. So we're going to stop halfway through and have you raise your hand if you have questions. And then again, towards the end, we have a microphone, and we'll bring it over to you traditional style.

Questions & Answers

Laura Sutcliffe
UBS Investment Bank, Research Division - Equity Research Analyst

So if you could just give us a couple of words about yourself and the things you're sort of most

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot